Literature DB >> 29109594

ARMA Cholesky Factor Models for the Covariance Matrix of Linear Models.

Keunbaik Lee1, Changryong Baek1, Michael J Daniels2.   

Abstract

In longitudinal studies, serial dependence of repeated outcomes must be taken into account to make correct inferences on covariate effects. As such, care must be taken in modeling the covariance matrix. However, estimation of the covariance matrix is challenging because there are many parameters in the matrix and the estimated covariance matrix should be positive definite. To overcomes these limitations, two Cholesky decomposition approaches have been proposed: modified Cholesky decomposition for autoregressive (AR) structure and moving average Cholesky decomposition for moving average (MA) structure, respectively. However, the correlations of repeated outcomes are often not captured parsimoniously using either approach separately. In this paper, we propose a class of flexible, nonstationary, heteroscedastic models that exploits the structure allowed by combining the AR and MA modeling of the covariance matrix that we denote as ARMACD. We analyze a recent lung cancer study to illustrate the power of our proposed methods.

Entities:  

Keywords:  Cholesky decomposition; heteroscedastic; longitudinal data

Year:  2017        PMID: 29109594      PMCID: PMC5669060          DOI: 10.1016/j.csda.2017.05.001

Source DB:  PubMed          Journal:  Comput Stat Data Anal        ISSN: 0167-9473            Impact factor:   1.681


  5 in total

1.  Marginally specified logistic-normal models for longitudinal binary data.

Authors:  P J Heagerty
Journal:  Biometrics       Date:  1999-09       Impact factor: 2.571

2.  Modelling the random effects covariance matrix in longitudinal data.

Authors:  Michael J Daniels; Yan D Zhao
Journal:  Stat Med       Date:  2003-05-30       Impact factor: 2.373

3.  Maximum likelihood estimation for incomplete repeated-measures experiments under an ARMA covariance structure.

Authors:  J Rochon; R W Helms
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

4.  Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Authors:  Seung Tae Kim; Ji Eun Uhm; Jeeyun Lee; Jong-mu Sun; Insuk Sohn; Seon Woo Kim; Sin-Ho Jung; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  Lung Cancer       Date:  2012-01       Impact factor: 5.705

5.  Modeling Covariance Matrices via Partial Autocorrelations.

Authors:  M J Daniels; M Pourahmadi
Journal:  J Multivar Anal       Date:  2009-11-01       Impact factor: 1.473

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.